Real-world Clinical Effectiveness & Safety LV009, an in Vivo CAR-T for the Treatment of Hematologic Cancers, Auto-immune Diseases & HLA/ AAV Sensitization.

by | Oct 14, 2026 | Clinical Trials | 0 comments

​ Conditions: HLA/AAV Sensitization; Auto-immune Diseases; Hematologic Cancers

Interventions: Genetic: LV009

Sponsors: Healthy Malaysia Association

Not yet recruiting Conditions: HLA/AAV Sensitization; Auto-immune Diseases; Hematologic Cancers
Interventions: Genetic: LV009
Sponsors: Healthy Malaysia Association
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *